DOI:
10.1055/s-00023610
Drug Research
LinksClose Window
References
Samukawa Y, Sata M, Furihata K. et al.
Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With
Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study.
Clin Pharmacol Drug Dev 2017;
6: 439-447
We do not assume any responsibility for the contents of the web pages of other providers.